AIM ImmunoTech Inc.
Close on Oct 19, 2026
- Market cap
- $2.79M
- P/E (TTM)
- –
- Dividend yield
- –
About AIM ImmunoTech
Biological Products, (No Diagnostic Substances), SIC 2836
AIM ImmunoTech Inc. is an immuno-pharma company focused on research and development of therapeutics to treat multiple types of cancer, viral diseases, and immune-deficiency disorders with inadequate or unmet treatments. Its primary products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA molecule being evaluated across various solid tumor types, including late-stage pancreatic cancer, as well as viral illnesses and immune disorders. The company aims to develop treatments for healthcare providers and patients facing severe diseases, including post-COVID conditions and chronic fatigue syndrome.
The company operates out of Ocala, Florida, where its principal executive offices are located. Its clinical trial activities and development collaborations take place internationally, including studies conducted in the Netherlands. Ampligen is approved for commercial sale in the Argentine Republic for severe chronic fatigue syndrome, though it has not received FDA approval or commercial marketing authorization in the United States.
Summary of the business section of AIM ImmunoTech's latest annual report, written by StockData.
Company profile
Company
- Legal name
- AIM ImmunoTech Inc.
- Headquarters
- Ocala, FL
- Address
- 2117 Sw Highway 484 32801
- Phone
- (352) 448-7797
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C., Miami, Florida
Stock & identifiers
- Ticker
- AIM
- Exchange
- NYSE
- Shares outstanding
- 30M, Aug 7, 2026
- Public float
- $6.41M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-100 reverse, Aug 14, 2025; 1-for-100 reverse, Jun 12, 2025; 1-for-44 reverse, Aug 14, 2019; 1-for-44 reverse, Jun 11, 2019; 1-for-12 reverse, Nov 14, 2016; 1-for-12 reverse, Aug 29, 2016
- SEC CIK
- 946644
- CUSIP
- 00901B303
- ISIN
- US00901B3033
- EIN
- 52-0845822
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Thomas K. Equels | CEO & President, Director | 139,822 |
| Peter W. Rodino III | COO, Secretary, Gen. Counsel | 401,762 |
| David I. Chemerow | Director | 31,882 |
| Ted D. Kellner | Director | 2,006,709 |
| William M. Mitchell | Director | 522,103 |
| Nancy Bryan | Director | 291,882 |
| Stewart Appelrouth | Director | 388,729 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Thomas K. Equels | $640.24K | $640.24K | $246.04K | $4 | – |
| FY2024 Thomas K. Equels | $1.09M | $1.07M | $285.94K | $64 | – |
| FY2023 Thomas K. Equels | $1.43M | $1.46M | $369.86K | $142 | – |
| FY2022 Thomas K. Equels | $1.35M | $1.24M | $332.11K | $34 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Corporate history
Events identified from SEC filings